Caelus Pharmaceuticals was founded early 2014, as a spin-off from the Academic Medical Center Amsterdam (AMC) and Wageningen University. Caelus develops novel treatment-strategies for cardiometabolic diseases based on improving intestinal microbial composition. The first product is a novel probiotic based on the patented therapeutic activity of a single bacterial strain (E.hallii) for the treatment of insulin resistance in obese people.
Investors 2
| Date | Name | Website |
| - | Life Scien... | lsfamsterd... |
| 22.02.2023 | UvA Ventur... | uvaventure... |